Hyperlipidemia Drugs Market Report by Drug Type (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, and Others), End User (Hospitals, Clinics, and Others), and Region 2024-2032
세계의 고지혈증 치료제 시장 규모는 2023년 227억 달러에 달했습니다. 향후 IMARC Group은 시장이 2032년까지 268억 달러에 이를 전망이고, 예측 기간 동안 복합 연간 성장률(CAGR)은 1.8%가 될 것으로 예측했습니다.
고지혈증(고 콜레스테롤 혈증)은 혈류 중 지방 수준이 높은 것을 특징으로 하는 의료 질환을 말합니다. 고지혈증은 지질/리포단백질 수준의 비정상적인 상승으로 뇌졸중, 말초 혈관 질환, 아테롬성 동맥 경화증, 당뇨병, 비만, 고혈압, 심혈관 질환을 유발합니다. 고지혈증은 일반적으로 유전적 요인, 건강에 해로운 생활 습관, 부적절한 식단으로 인해 발생합니다. 일반적으로 사용되는 고지혈증 치료제는 스타틴계 약제, PCSK9 억제제, 담즙산 분비 억제제, 피브린산 유도체, 피브레이트계 약제 등을 포함합니다. 이 약은 간에서 콜레스테롤 생산 수준을 낮추는 동시에 혈류에서 콜레스테롤을 제거합니다.
세계에서 고지혈증의 유병률이 증가하고 있는 것은 시장 성장을 가속하는 중요한 요인 중 하나입니다. 게다가 높은 콜레스테롤 수치와 심혈관 질환에 걸리기 쉬운 노인 인구 증가도 시장 성장을 뒷받침하고 있습니다. 이에 따라 대중들 사이에서 건강 의식이 높아지고 고콜레스테롤혈증의 이용 가능한 치료법에 대한 인식이 높아지고 있는 것도 시장 성장을 뒷받침하고 있습니다. 게다가 효능을 높인 신규 약제 클래스의 개발 등 다양한 기술의 진보도 성장을 가속하는 요인이 되고 있습니다. 이 약물은 내피 기능과 동맥 경화 플라크의 안정성을 향상시켜 염증과 세포 손상을 최소화합니다. 그 밖의 요인으로는 바이오메디컬 과학부문에서의 광범위한 연구개발(R&D) 활동과 세계의 의료 인프라의 전반적인 개선 등을 들 수 있으며 시장의 추가 견인역이 될 것으로 예상됩니다.
이 보고서에서 다루는 주요 질문
- 2023년 세계의 고지혈증 치료제 시장 규모는?
- 예측 기간 동안 세계의 고지혈증 치료제 시장의 예상 성장률은?
- 세계의 고지혈증 치료제 시장을 견인하는 주요 요인은?
- 세계의 고지혈증 치료제 시장에 대한 COVID-19의 영향은?
- 의약품 유형별 고지혈증 치료제 시장의 세계의 내역은?
- 세계의 고지혈증 치료제 시장의 최종 사용자별 내역은?
- 세계의 고지혈증 치료제 시장의 주요 지역은?
- 세계의 고지혈증 치료제 시장에서 주요 진출기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 고지혈증 치료제 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 의약품 유형별
- 스타틴
- 담즙산 포착제
- 콜레스테롤 흡수 억제제
- PCSK9 억제제
- 기타
제7장 시장 내역: 최종 사용자별
제8장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 참가업체의 위협
- 대체품의 위협
제12장 가격 분석
제13장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Amgen Inc.
- AstraZeneca Plc
- Daiichi Sankyo Company Limited
- Eli Lilly and Company
- Esperion Therapeutics Inc.
- GlaxoSmithKline Pharmaceuticals Limited(GlaxoSmithKline Plc)
- Immuron Limited
- Ionis Pharmaceuticals Inc.
- Merck & Co. Inc.
- Pfizer Inc.
- Sanofi SA
BJH
The global hyperlipidemia drugs market size reached US$ 22.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 26.8 Billion by 2032, exhibiting a growth rate (CAGR) of 1.8% during 2024-2032.
Hyperlipidemia, or high cholesterol, refers to a medical ailment characterized by high levels of fats in the bloodstream. It is the abnormal elevation of lipids and/or lipoprotein levels that can lead to stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension, and cardiovascular diseases. It is usually caused by genetic factors, unhealthy lifestyles and inadequate diet. Some of the commonly used hyperlipidemia drugs include statins, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors, bile acid sequestrants, fibric acid derivatives or fibrates and combination and miscellaneous antihyperlipidemic agents. These drugs reduce cholesterol production levels in the liver while further removing it from the bloodstream.
The increasing prevalence of hyperlipidemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to high levels of cholesterol and cardiovascular diseases, is also driving the market growth. In line with this, rising health consciousness among the masses and growing awareness regarding the available treatment alternatives for hypercholesterolemia is also favoring the market growth. Additionally, various technological advancements, such as the development of novel drug classes with enhanced efficacy, are acting as other growth-inducing factors. These drugs offer improved endothelial function and stability of atherosclerotic plaques and cause minimal inflammation and damage to the cells. Other factors, including the extensive research and development (R&D) activities in the field of biomedical sciences, along with overall improvements in the healthcare infrastructure across the globe, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hyperlipidemia drugs market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug type and end user.
Breakup by Drug Type:
Statins
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
PCSK9 Inhibitors
Others
Breakup by End User:
Hospitals
Clinics
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.
Key Questions Answered in This Report
- 1. What was the size of the global hyperlipidemia drugs market in 2023?
- 2. What is the expected growth rate of the global hyperlipidemia drugs market during 2024-2032?
- 3. What are the key factors driving the global hyperlipidemia drugs market?
- 4. What has been the impact of COVID-19 on the global hyperlipidemia drugs market?
- 5. What is the breakup of the global hyperlipidemia drugs market based on the drug type?
- 6. What is the breakup of the global hyperlipidemia drugs market based on the end user?
- 7. What are the key regions in the global hyperlipidemia drugs market?
- 8. Who are the key players/companies in the global hyperlipidemia drugs market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Hyperlipidemia Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Drug Type
- 6.1 Statins
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Bile Acid Sequestrants
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Cholesterol Absorption Inhibitors
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 PCSK9 Inhibitors
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by End User
- 7.1 Hospitals
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Clinics
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.2 Asia Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Amgen Inc.
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 AstraZeneca Plc
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 Daiichi Sankyo Company Limited
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 Eli Lilly and Company
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Esperion Therapeutics Inc.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.6 GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.6.4 SWOT Analysis
- 13.3.7 Immuron Limited
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.8 Ionis Pharmaceuticals Inc.
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.8.4 SWOT Analysis
- 13.3.9 Merck & Co. Inc.
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
- 13.3.10 Pfizer Inc.
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.10.3 Financials
- 13.3.10.4 SWOT Analysis
- 13.3.11 Sanofi S.A.
- 13.3.11.1 Company Overview
- 13.3.11.2 Product Portfolio
- 13.3.11.3 Financials
- 13.3.11.4 SWOT Analysis
